BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31385309)

  • 1. Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
    Pulsoni A; Della Starza I; Cappelli LV; Tosti ME; Annechini G; Cavalli M; De Novi LA; D'Elia GM; Grapulin L; Guarini A; Del Giudice I; Foà R
    Br J Haematol; 2020 Jan; 188(2):249-258. PubMed ID: 31385309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
    Cavalli M; De Novi LA; Della Starza I; Cappelli LV; Nunes V; Pulsoni A; Del Giudice I; Guarini A; Foà R
    Br J Haematol; 2017 May; 177(4):588-596. PubMed ID: 28419517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
    Galimberti S; Luminari S; Ciabatti E; Grassi S; Guerrini F; Dondi A; Marcheselli L; Ladetto M; Piccaluga PP; Gazzola A; Mannu C; Monitillo L; Mantoan B; Del Giudice I; Della Starza I; Cavalli M; Arcaini L; Tucci A; Palumbo GA; Rigacci L; Pulsoni A; Vitolo U; Boccomini C; Vallisa D; Bertoldero G; Gaidano G; Musto P; Petrini M; Federico M
    Clin Cancer Res; 2014 Dec; 20(24):6398-405. PubMed ID: 25316810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
    Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
    Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
    Drandi D; Ferrero S; Ladetto M
    Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
    Ladetto M; Lobetti-Bodoni C; Mantoan B; Ceccarelli M; Boccomini C; Genuardi E; Chiappella A; Baldini L; Rossi G; Pulsoni A; Di Raimondo F; Rigacci L; Pinto A; Galimberti S; Bari A; Rota-Scalabrini D; Ferrari A; Zaja F; Gallamini A; Specchia G; Musto P; Rossi FG; Gamba E; Evangelista A; Vitolo U;
    Blood; 2013 Nov; 122(23):3759-66. PubMed ID: 24085766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?
    Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
    Leuk Lymphoma; 2015; 56(8):2350-6. PubMed ID: 25426666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
    Della Starza I; Cavalli M; De Novi LA; Genuardi E; Mantoan B; Drandi D; Barbero D; Ciabatti E; Grassi S; Gazzola A; Mannu C; Agostinelli C; Piccaluga PP; Bomben R; Degan M; Gattei V; Guarini A; Foà R; Galimberti S; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2019 Oct; 37(4):368-374. PubMed ID: 31325190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.
    Delfau-Larue MH; Boulland ML; Beldi-Ferchiou A; Feugier P; Maisonneuve H; Casasnovas RO; Lemonnier F; Pica GM; Houot R; Ysebaert L; Tilly H; Eisenmann JC; Le Gouill S; Ribrag V; Godmer P; Glaisner S; Cartron G; Xerri L; Salles GA; Fest T; Morschhauser F
    Blood Adv; 2020 Aug; 4(14):3217-3223. PubMed ID: 32673385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
    Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
    Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
    Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.
    Galimberti S; Ciabatti E; Ercolano G; Grassi S; Guerrini F; Cecconi N; Rousseau M; Cervetti G; Mazziotta F; Iovino L; Falzetti F; Falcinelli F; Bosi A; Rigacci L; Kovalchuk S; Vallisa D; Macchia L; Ciancia E; Petrini M
    Front Pharmacol; 2017; 8():413. PubMed ID: 28706485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response monitoring in follicular lymphoma by synchronous evaluation of minimal residual disease and diffusion-weighted MRI.
    Meleshko AN; Kharuzhyk SA; Piatrouskaya NA
    Exp Oncol; 2015 Dec; 37(4):295-7. PubMed ID: 26710844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
    Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
    Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab.
    Hirt C; Schüler F; Dölken G
    Semin Cancer Biol; 2003 Jun; 13(3):223-31. PubMed ID: 12959353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
    Cencini E; Puccini B; Rigacci L; Fabbri A; Kovalchuk S; Mannelli L; Benelli G; Carfagno T; Simontacchi G; Bocchia M; Bosi A
    Leuk Lymphoma; 2018 Jun; 59(6):1420-1426. PubMed ID: 28994343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of t(14;18) by PCR of IgH/BCL2 fusion gene in follicular lymphoma from archived cytological smears.
    Stoos-Veić T; Livun A; Ajduković R; Pejsa V; Jaksić O; Kusec R
    Coll Antropol; 2010 Jun; 34(2):425-9. PubMed ID: 20698113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.